Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa

PHASE4CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

May 31, 2012

Conditions
HIV
Interventions
DRUG

Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC

Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID

Trial Locations (1)

Unknown

Chelstone Clinic, Lusaka

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Toronto

OTHER

collaborator

Abbott

INDUSTRY

lead

University of Zambia

OTHER